The data from the Lauren classification of the ADAMTS mRNA expression of the GC patients showed that the patients with high expression of diffuse ADAMTS5 (Affymetrix ID: 235368_at) gene, intestinal ADAMTS1 (Affymetrix ID: 222486_s_at), ADAMTS2 (Affymetrix ID: 226311_at), ADAMTS3 (Affymetrix ID: 214913_at), ADAMTS4 (Affymetrix ID: 214913_at), ADAMTS6 (Affymetrix ID: 237411_at) or ADAMTS7 (Affymetrix ID: 228911_at) had shorter survival time compared with those with low expression (Figures 11 and 12 and Table 6). This evidence concerns the gene ADAMTS1 and gastric cancer.